Blinatumomab
Blinatumomab 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Acute Lymphoblastic Leukemia、Philadelphia Chromosome-Positive、Acute Lymphoblastic Leukemia (ALL)、Stem Cell Transplant。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
24 项
全球在招研究
7 项
已进入 III/IV 期
25 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- Northside Hospital, Inc.
- M.D. Anderson Cancer Center
- Bambino Gesù Hospital and Research Institute
- Children's Oncology Group
- Merck Sharp & Dohme LLC
- The Children's Hospital of Zhejiang University School of Medicine
- Charite University, Berlin, Germany
- Ascentage Pharma Group Inc.
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
美国、澳大利亚、加拿大、新西兰、Puerto Rico、丹麦、法国、Greece、Israel、意大利、日本、荷兰
正在招募患者的 Blinatumomab 研究
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
III 期招募中美国澳大利亚加拿大新西兰NCT03959085A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)
II 期 / III 期招募中加拿大丹麦法国GreeceNCT07570173Blinatumomab for CNI-Resistant/Intolerant SRNS in Children
I 期招募中中国NCT06607991International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)
III 期招募中奥地利比利时Czechia丹麦NCT07476729Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab
I 期 / II 期招募中美国NCT06287229Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
I 期招募中美国加拿大NCT04260022TCRαβ-depleted Progenitor Cell Graft With Early Memory T-cell DLI, Plus Selected Use of Blinatumomab, in naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies
I 期招募中美国NCT07052370TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II
I 期 / II 期招募中美国加拿大NCT05848687Blinatumomab and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL
I 期招募中中国NCT06507514ALL Backbone in AYAs
II 期招募中美国NCT07227584ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL
不适用招募中中国NCT07454226A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
II 期招募中美国澳大利亚加拿大Puerto RicoNCT06124157Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
I 期 / II 期招募中美国NCT06308588Full-course Immunotherapy Combined With Chemotherapy in Newly Diagnosed B-cell Acute Lymphoblastic Leukemia
II 期招募中中国NCT07564453A 3-cohort Randomized Study Evaluating the Role of New Immunotherapeutic Agents and of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Frontline Therapy of Adults With Acute Lymphoblastic Leukemia
II 期 / III 期招募中法国NCT06860269Combined Immuno-chemotherapy for Patients With B-linear Acute Lymphoblastic Leukemia Diagnosed From 0 to 365 Days of Life (ALL-Baby-2021)
III 期招募中RussiaNCT05029531Subcutaneous Blinatumomab for Treatment of Adult Patients With CD19-Positive Mixed Phenotype Acute Leukemia (MPAL)
II 期招募中美国NCT07222579Multicenter Study of Combined Chemotherapy and Transplantation for Adult ALL
II 期 / III 期招募中中国NCT07059156Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017
III 期招募中澳大利亚奥地利Czechia德国NCT03643276ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML
I 期招募中美国NCT03595917RDC-Blinatumomab Versus hyperCVAD for Ph-negative B-ALL.
II 期招募中中国NCT06250959Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia
I 期 / II 期招募中美国NCT01371630Blinatumomab Plus Reduced-dose Chemotherapy in Treating B-ALL
II 期招募中中国NCT06742515Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blinatumomab and SCT
II 期招募中德国NCT06061094
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。